Current disease status-Recurrent leukemia - Page 4 of 8 Posts on Medivizor
Navigation Menu

Current disease status-Recurrent leukemia Posts on Medivizor

The safety and effectiveness of nilotinib in the treatment of unresponsive CML

Posted by on Aug 20, 2018 in Leukemia | 0 comments

In a nutshell This study examined the safety and effectiveness of using nilotinib (Tasigna) in patients with chronic myeloid leukemia (CML) unresponsive to other treatment. The study concluded that nilotinib is safe and effective in the treatment of CML unresponsive to imatinib (Gleevec). Some background Chronic myeloid leukemia is a cancer of the...

Read More

Outcomes and management of CLL treated with venetoclax

Posted by on Aug 20, 2018 in Leukemia | 0 comments

In a nutshell This study examined the safety and effectiveness of venetoclax (Venclexta) in the treatment of chronic lymphocytic leukemia (CLL). Researchers found that venetoclax was safe and effective in these patients. Some background Chronic lymphocytic leukemia is a type of cancer of the bone marrow that can lead to an abnormal immune system. Over...

Read More

Nilotinib versus imatinib in the treatment of CML

Posted by on Aug 13, 2018 in Leukemia | 0 comments

In a nutshell This study compared the effectiveness of nilotinib (Tasigna) with high-dose imatinib (Glivec) in patients with unresponsive chronic myeloid leukemia. Researchers concluded that nilotinib may be more effective as a long-term treatment for CML when compared to imatinib. Some background Chronic myeloid leukemia is a cancer of the bone...

Read More

What major factors affect disease progression and outcome in adults with acute myeloid leukemia?

Posted by on Aug 1, 2018 in Leukemia | 0 comments

In a nutshell This study examined the major factors associated with disease progression and outcomes in adults with acute myeloid leukemia (AML). The authors found that younger age, less molecular mutations and choice of induction therapy were all positively associated with higher rates of complete remission and survival. Some background A number...

Read More

The safety of blinatumomab in the treatment of ALL

Posted by on Jul 30, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the safety and effectiveness of blinatumomab (Blincyto) compared with standard chemotherapy in the treatment of acute lymphoblastic leukemia (ALL). The study found that blinatumomab was a safe and effective treatment option compared to chemotherapy in patients with ALL. Some background Acute lymphoblastic leukemia is...

Read More

Is mismatched donor stem cell transplantation an effective treatment in high-risk relapse of ALL?

Posted by on Jun 25, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the effectiveness of mismatched donor stem cell transplantation (SCT) for treating children with high-risk relapse of acute lymphoblastic leukemia (ALL). Researchers found that mismatched donor SCT was useful but not as effective as matched donor SCT in children with high-risk ALL. Some background Acute lymphoblastic...

Read More

Does ibrutinib pre-treatment affect the outcomes of alloHCT for patients with CLL?

Posted by on May 31, 2018 in Leukemia | 0 comments

In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with chronic lymphocytic leukemia (CLL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of...

Read More

Is thiotepa-based reduced-intensity conditioning effective before cord blood stem cell transplantation?

Posted by on May 31, 2018 in Leukemia | 0 comments

In a nutshell This study examined the effectiveness of thiotepa-based RIC in leukemia and lymphoma patients undergoing stem cell transplantation. The authors concluded that this treatment improved outcomes compared to standard RIC. Some background Before undergoing stem cell transplantation, patients with lymphoma or leukemia must undergo conditioning...

Read More

Can chronic myeloid leukemia patients discontinue dasatinib after a year of deep molecular response?

Posted by on May 12, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if dasatinib could be successfully discontinued in chronic myeloid leukemia patients who were receiving it as a second line treatment after a year of deep molecular response. This study concluded that it was possible to discontinue dasatinib use in this group of patients. Some background Imatinib...

Read More

Sorafenib to improve outcome after transplant for patients with FLT3-ITD acute myeloid leukemia

Posted by on May 1, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the effect of sorafenib (Nexavar) on the outcomes of patients with acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3)–internal tandem duplication (ITD) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study concluded that sorafenib before or after...

Read More